The Chemours Company (CC) Q4 2024 earnings summary

Executive summary

• Exceeded Q4 2024 Adjusted EBITDA expectations, driven by operational excellence, cost savings, and strong Opteon™ refrigerant growth, despite challenging macroeconomic conditions.

• Achieved record TSS sales with 23% YoY growth in Opteon Refrigerants; TT Adjusted EBITDA up 20% YoY in Q4 and 8% in FY24.

• Fully remediated four material weaknesses in internal controls identified earlier in 2024.

• Launched new executive leadership and 'Pathway to Thrive' strategy to support strategic execution.

• Returned $148M to shareholders via dividends in 2024.

Financial highlights

• Q4 2024 net sales: $1.4B, down 1% YoY; Adjusted EBITDA: $179M, up 2% YoY; Q4 net loss: $8M ($0.05/share); Adjusted Net Income: $16M ($0.11/share).

• Full-year 2024 net sales: $5.8B, down 5% YoY; Adjusted EBITDA: $786M, down from $1B YoY.

• Full-year net income: $86M ($0.57/share) vs. prior-year net loss of $238M; Adjusted Net Income: $182M ($1.21/share), down from $425M YoY.

• Operating cash flow: $138M in Q4; full-year outflow: $633M, impacted by settlement and working capital unwind.

• Gross margin for 2024 was 19.9%, down from 21.5% in 2023.

Outlook and guidance

• 2025 Adjusted EBITDA expected between $825M–$975M; capex guidance $250M–$300M; operating cash flow expected to improve and cover capex and dividends.

• TSS to see double-digit Opteon™ sales growth; Freon™ prices to remain low.

• TT volumes stable, with regional mix impacting Q1; cost reduction targets remain.

• APM to face continued demand softness and unfavorable product mix in Q1.

• Q1 2025: TSS expects sequential net sales and EBITDA growth; TT and APM anticipate sequential declines.